The current vaccines for anthrax in the United States and United Kingdom are efficacious in the two most accepted animal models of inhalation anthrax, nonhuman primates and rabbits, but require extensive immunization protocols. We previously demonstrated that a linear determinant in domain 2 of Bacillus anthracis protective Ag (PA) is a potentially important target for an epitopespecific vaccine for anthrax, as Abs specific for this site, referred to as the loop-neutralizing determinant (LND), neutralize lethal toxin in vitro, yet are virtually absent in PA-immunized rabbits. In this study, we evaluated the immunogenicity and protective efficacy in rabbits of multiple antigenic peptides (MAPs) consisting of aa 304-319 from the LND of PA colinearly synthesized at the C terminus (T-B MAP) or N terminus (B-T MAP) with a heterologous T cell epitope from Plasmodium falciparum. Immunogenicity studies demonstrated that both MAPs elicited toxin-neutralizing Ab in rabbits. To evaluate the MAPs as potential anthrax vaccines, we immunized groups of rabbits (n = 7) with each MAP in Freund's adjuvant and then exposed all rabbits to a 200-LD 50 challenge with aerosolized spores of B. anthracis Ames strain. All seven rabbits immunized with the B-T MAP and 89% (six of seven) of rabbits immunized with the T-B MAP survived the spore challenge. Corollary studies with reference sera from human vaccinees immunized with rPA or anthrax vaccine absorbed and nonhuman primates immunized with PA revealed no detectable Ab with specificity for the LND. We conclude that a synthetic peptide vaccine targeting the LND would be a potentially efficacious vaccine for anthrax. The Journal of Immunology, 2010, 185: 3661-3668. I nhalation anthrax, resulting from exposure to aerosolized spores of Bacillus anthracis, is an important threat to both military and civilian populations (1) . The morbidity and mortality associated with inhalation anthrax are primarily a result of the effects of two toxins, lethal toxin (LeTx) and edema toxin. These are classic A-B toxins, with lethal factor (LF) and edema factor (EF) representing the active moieties (A) and protective Ag (PA), the cell-binding moiety (B) (2) (3) (4) . The 83-kDa full-length PA binds the anthrax toxin receptor TEM8 or CMG2 on the cell surface, and is then cleaved by a furin-like protease releasing a 20-kDa fragment and enabling generation of heptamers and oligomers of PA63 (5) . Oligomerized PA63 forms prepores, which, after trafficking to an endosomal compartment, facilitate transport of EF and LF into the cytosol, where they exert their enzymatic activities as edema toxin and LeTx, respectively (2) (3) (4) .
Abs to PA can successfully mediate protection from B. anthracis challenges in animal models of inhalation anthrax, and the protection is correlated with the ability of the Abs to neutralize LeTx in vitro in the toxin neutralization assay (TNA) (6) (7) (8) (9) (10) (11) . The effective elicitation of PA-specific toxin-neutralizing Abs underlies the protective efficacy of the currently accepted vaccines for anthrax in the United States and United Kingdom, anthrax vaccine absorbed (AVA, Biothrax) and anthrax vaccine precipitated (AVP), respectively, which both consist of acellular culture filtrates of B. anthracis formulated with aluminum adjuvants (12, 13) . Findings from an early field trial of a similar vaccine studied in goat hair workers, and more recent rabbit and nonhuman primate (NHP) studies, suggest that such vaccines confer significant protection from inhalation spore challenges (7, 11, (14) (15) (16) . However, the extensive immunization protocol required for establishment and maintenance of immunity has motivated commitment to the development of next generation anthrax vaccines, a course supported by a committee convened by the Institute of Medicine (17) (18) (19) .
PA remains the primary antigenic target for anthrax vaccines; however, other B. anthracis Ags are also being studied in an effort to broaden the repertoire of immune responses induced through vaccination (20) (21) (22) (23) (24) . This has been motivated in part by the realization, informed primarily from the analysis of PA-specific mAbs from mice and humans, that with few exceptions, the Abs responsible for LeTx neutralization are focused primarily on regions in domains 19 and 4 of PA63, which are involved in binding to LF and EF, and to the anthrax toxin receptors, respectively (25) (26) (27) (28) (29) (30) (31) (32) (33) . Limited breadth of the neutralizing repertoire induced through immunization with PA could theoretically leave vaccinees vulnerable to strains of B. anthracis maliciously altered to evade the neutralizing specificities, a contingency for which proof-of-principle has now been demonstrated (34, 35) .
We previously showed that immunization of rabbits with multiple antigenic peptides (MAPs) displaying aa 304-319 or 305-319 from domain 2 of PA elicits Abs specific for a linear determinant in PA, which mediated high-titer neutralization of LeTx in vitro (36, 37) . The target of these neutralizing Abs, referred to as the loop-neutralizing determinant (LND), is found within the 2b2-2b3 loop, a structure critical to the function of PA and essential for the translocation of EF and LF into the cytosol (38) (39) (40) (41) . Importantly, studies have shown that the LND appears to be immunologically silent in rabbits immunized with PA, as Abs to the sequence comprising the LND are present at very low or undetectable levels in the sera of PA-immune animals (37) . Additionally, there is also evidence that Abs to the LND may be present at functionally insignificant levels in human AVA serum (37, 42) . Abs to the LND, therefore, may be distinct from, and nonoverlapping with the repertoire of Abs elicited through immunization with PA-based vaccines.
The goal of the current study was to determine the protective efficacy of LND-specific peptide immunogens in the rabbit model of inhalation anthrax, and to evaluate the immune correlates of protection.
Materials and Methods

Synthetic peptides and recombinant proteins
MAPs displaying four branching copies per molecule of aa 304-319 (single-letter code: HGNAEVHASFFDIGGS, GenBank accession P13423) or aa 305-319 from PA colinearly synthesized at either the N or C terminus with a peptide corresponding to the T* helper epitope from the circumsporozoite protein of Plasmodium falciparum (aa 326-345 strain NF54, EYLNKIZNSLSTEWSPCSVT, GenBank accession AAA29527) (43) were synthesized using standard Fmoc chemistry. All peptides are linked at their C terminus to the lysine core of the MAP. Linear synthetic peptides used for the T cell proliferation assays include the following: aa 304-319 from PA linked at the C terminus to the T* helper epitope, aa 305-319 alone, and a negative control peptide (KSDNQIKAVPASQAL) representing aa 235-249 from the p38 egg Ag of Schistosoma mansoni (44) . The linear synthetic peptides used for inhibition studies were aa 304-319 from PA colinearly synthesized at the C terminus of a peptide corresponding to the P30 Th cell epitope (FNNFTVSFWLRVPKVSASHLE) from tetanus toxin (GenBank accession AAA23282) and a control peptide consisting of the P30 peptide alone (36, 45) . All synthetic peptides were synthesized commercially (SigmaGenosys, The Woodlands, TX). A recombinant protein displaying aa 299-327 (single-letter code: HTSEVHGNAEVHASFFDIGGSVSAGFSNS) from PA linked to maltose-binding protein was used for assessing LND peptidespecific immunity by ELISA (37) . The DNA sequence encoding the recombinant protein was validated with automated dideoxy sequencing of the sense and antisense DNA (46) , and the purified protein was found to be in excess of 90% pure by SDS-PAGE analysis.
Animals and immunizations
Twelve-week-old female C57BL/6, C3H, SJL, and BALB/c mice (The Jackson Laboratory, Bar Harbor, ME) were used for all mouse experiments. For proliferation assays, groups of mice (n = 5) were immunized once s.c. at the base of the tail with 12 nmol MAP in an emulsion with CFA. Female New Zealand White (NZW) rabbits (Covance Research Products, Denver, PA) were immunized on day 0 with 250 mg of the respective MAP or with control PA83 (List Biological Laboratories, Campbell, CA) in an emulsion with CFA and were then boosted four times at 2-wk intervals with 125 mg of the respective MAP or PA83 in an emulsion with IFA. Serum samples were collected prior to the first immunization (day 0) and ∼10 d after each booster immunization. Mice and rabbits were cared for in accordance with the standards of the Association for Assessment and Accreditation of Laboratory Animal Care, and all experiments and animal procedures were approved by an Institutional Animal Care and Use Committee.
ELISA
Ab responses were assessed by ELISA, essentially as described (37) . For analysis of Abs specific for PA, wells of microtiter plates (Immulon 2; Thermo Labsystems, Franklin MA) were coated overnight at 4˚C with 100 ng PA in a 0.05 M carbonate buffer (pH 9.5). For analysis of antipeptide binding, wells were coated with 500 ng recombinant protein displaying aa 299-327 of PA as a fusion with maltose-binding protein. Bound Ab was detected with secondary biotinylated Ab specific for either mouse or rabbit IgG or for rabbit IgM (Southern Biotechnology Associates, Birmingham, AL), followed by streptavidin-alkaline phosphatase and 4-nitrophenylphosphate (Roche, Indianapolis, IN). Absorbance at 405 nm minus absorbance at 650 nm was determined using an ELISA reader (Emax microplate reader; Molecular Devices, Menlo Park, CA). Ab titers were determined from serial 2-fold dilutions of individual rabbit serum and represent the reciprocal dilution at the EC 50 established using nonlinear regression to fit a variable slope sigmoidal equation to the serial dilution data using Prism 5.0 (GraphPad, San Diego, CA). The lower limit of quantitation for the ELISAwas 16 on immobilized PA and 8 on immobilized recombinant protein.
Toxin neutralization assay
The ability of Ab to block LeTx cytotoxicity in vitro was assessed using the RAW264.7 cell lines (American Type Culture Collection, Manassas, VA), as described (37) . For neutralization studies, 110 ng/ml PA was used along with 150 ng LF. The reciprocal of the effective dilution at which 50% of the cells are protected from cytotoxicity (ED 50 ) (47) was determined for each serum by using nonlinear regression to fit a variable slope sigmoidal equation to the serial dilution data set using Prism 5.0 (GraphPad). The TNA assay has a lower limit of quantification of 16. Samples with TNA titers below this limit were assigned a value of 16. For the analysis of peptide inhibition of TNA, experimental serum samples were preincubated with 16 mM peptide for 30 min prior to analysis in the TNA.
Aerosol spore challenges
After the final immunizations, rabbits were transported to Battelle Biomedical Research Center, where aerosol challenges were performed in a blinded study (Battelle Study Number 851-G006088). A second study (Battelle Study 1021-G006377) was performed subsequently to evaluate any protective efficacy associated with immunization with a control MAP in Freund's adjuvant. Rabbits were quarantined for 1 wk, and then randomly assigned to challenge on one of three successive days. Six age-matched female naive control rabbits were also challenged, two on each challenge day. Rabbits were challenged under Biological Safety Level III containment using a muzzle-only exposure to B. anthracis Ames strain spore aerosol generated by a Collison nebulizer with a target exposure of 200 LD 50 . Actual inhaled dose was determined for each animal using individual plethysmography data and spore concentration data from contemporaneous air sampling and spore quantitation by plating. One aerosol LD 50 of Ames spores in NZW rabbits is 1.05 3 10 5 spores (48). Aerosol challenge doses are listed as the mean LD 50 6 SD. Following challenge, animals were observed twice daily for a period of 14 d. Clinical observations were noted, and moribund animals were euthanized. Deaths were recorded on the day the animal was found dead or was euthanized. Animals surviving to day 14 were anesthetized, terminally bled, and euthanized.
NHP and human reference antisera
The following reagents were obtained through BEI Resources (Biodefense and Emerging Infections Research Resources Repository, Manassas, VA). NR-719 (Human Anti-AVA Reference Serum AVR801 Lot 2) is a pooled standard reference serum derived from healthy human donors that have been vaccinated with AVA, NR-715 is a high-activity human polyclonal anti-PA antiserum prepared from pooled defibrinated plasma from three human subjects vaccinated with PA, NR9327 is a rhesus macaque anti-PA antiserum prepared from pooled sera from 20 animals vaccinated i.m. with rPA adsorbed to Alhydrogel, and NR9331 is a cynomolgus macaque anti-PA antiserum prepared from pooled sera from 20 animals vaccinated i.m. with rPA adsorbed to Alhydrogel.
Statistical analysis
For determination of ELISA EC 50 titers and TNA ED 50 titers, fourparameter logistic regression was used to fit variable slope sigmoidal equations to the serial dilution data. For comparisons of Ab and neutralization titers between two groups, the Mann-Whitney U test was employed. The Kruskal-Wallis test was used for comparisons involving more than two groups. The Kaplan-Meier method was used to plot survival data, and statistical differences in survival curves between groups were compared using the Mantel-Cox log-rank test. All statistical analysis was performed using GraphPad Prism software version 5 (GraphPad).
Results
The LND MAP stimulates T cells in MHC-disparate inbred mice
A previous study showed that the LND peptide sequence comprising aa 305-319 from PA is devoid of Th cell epitopes in diverse strains of mice, and demonstrated that in MAP form, the linkage of the LND peptides to the P30 Th cell epitope from tetanus toxin improved the subsequent immunogenicity of MAPs in rabbits compared with a simple MAP displaying only the LND peptide without a helper epitope (36) . An interest in identifying a complementary or alternative Th cell epitope to P30 led us in the current study to evaluate the T* helper epitope from the circumsporozoite protein of P. falciparum, because this epitope has been shown to be stimulatory in inbred mice, NHPs, and humans (43, (49) (50) (51) . To assess the likelihood that T cells from outbred rabbits would respond to the T* epitope and thereby support the production of Ab to the LND peptide, we evaluated the ability of a MAP comprising the T* helper epitope, colinearly synthesized with the 304-319 peptide at the C terminus, to stimulate T cells in four strains of MHC-disparate mice. Pooled lymph node cells from all four strains of T-B MAP-immune mice were capable of restimulation in vitro in the presence of the T*-containing MAP or with the linear T*-containing synthetic peptide (Fig. 1) . As expected, there was no proliferation to the LND peptide sequence, which was previously shown to be devoid of helper epitopes in the four strains of mice tested (36) .
Immunogenicity of LND MAPs in rabbits
Having shown that the T* epitope was capable of stimulating T cell responses in four diverse strains of inbred mice, and was therefore likely to stimulate T cell help in outbred rabbits, we proceeded with immunogenicity studies to evaluate MAPs displaying the T* helper epitope colinearly synthesized at the N or C termini of the peptide sequences aa 304-319 or aa 305-319 from PA. The evaluation of the MAPs synthesized with contrasting orientations of T and B cell epitopes was prompted by earlier work demonstrating that the orientation of sequences within MAPs can have pronounced effects on immunogenicity (52) . Groups of rabbits (n = 3) were immunized five times at 2-wk intervals with one of four MAPs in CFA for priming immunizations and IFA for boosting immunizations. All MAPs were immunogenic in both the T-B (T cell epitope at N terminus of MAP; B cell epitope at C terminus) and B-T orientation, and neutralizing Ab was elicited in all groups (Fig. 2) .
Aerosol spore challenge
Two MAPs were evaluated for efficacy in protecting rabbits from an aerosol challenge with B. anthracis. For this study, seven female NZW rabbits per group were immunized with a MAP comprising the T* helper epitope colinearly synthesized with the 304-319 peptide at either the N terminus (B-T MAP) or C terminus (T-B MAP), or with soluble PA (positive control) five times at 2-wk intervals using CFA for priming immunizations and IFA for booster immunizations. Age-matched naive rabbits served as a nonimmune control group (n = 6). Although exclusively a research adjuvant, Freund's was chosen for these studies because this work builds on the preliminary immunogenicity studies with the LND MAPs using this adjuvant, and the challenge was designed to maximize the sensitivity for assessing whether LND-specific Ab can mediate protection in rabbits from anthrax spore challenge.
Approximately 3 wk after their final immunization, all rabbits were exposed to a targeted aerosol dose of 200 LD 50 
Serological responses after immunization and challenge
In vitro analysis of prechallenge rabbit serum obtained after the final immunization demonstrated that the single T-B MAP-immune rabbit that succumbed to infection had the lowest Ab titers (anti-LND peptide titer = 8,456; anti-PA titer = 7,240) and was negative for TNA activity among that group of rabbits (Fig. 4 , open triangles). One rabbit from the B-T MAP group had similar prechallenge anti-LND peptide titer (6,586) and anti-PA titer (8,558) and was also negative for TNA activity (Fig. 4, open squares) , but survived challenge. This rabbit developed a strong IgG boost consistent with an anamnestic response with postchallenge anti-LND peptide, anti-PA, and TNA titers of 35,991, 45,888, and 12,609, respectively (Fig. 4, open squares) . As indicated by the ELISA data, most of Ab in the postchallenge serum from this rabbit was LND specific and did not primarily represent de novo PA-specific Ab. This was further demonstrated by the finding that .85% of all neutralization activity detectable in the postchallenge serum from this rabbit was completely inhibitable with the LND peptide (Fig. 5) .
Analysis of prechallenge serum from all MAP-immunized rabbits demonstrated that the T-B MAP (anti-PA geometric mean titer
[GMT] = 24,681; anti-LND peptide GMT = 21,878) rabbits had higher anti-PA and anti-LND peptide Ab titers than the B-T MAP group (anti-PA GMT = 11,499, anti-LND peptide GMT = 9,459), although the differences did not reach statistical significance (p = 0.0728 for PA; p = 0.0728 for LND peptide). All rabbits immunized with PA also developed high titer Ab responses to PA with a GMT of 82,651, but consistent with earlier studies (37), serum from these rabbits did not have meaningful levels of Ab specific for the LND peptide sequence with a GMT of 145 (Fig. 4A, 4C) . With the exception of the two aforementioned rabbits, prechallenge serum from all B-T and T-B MAP-immune rabbits demonstrated toxin neutralization with GMTs of 549 and 1,651, respectively, as did all PAimmune rabbits with a GMT of 1,954 (Fig. 4E, 4F) .
Anti-PA and anti-LND peptide Ab responses in the postchallenge serum from rabbits in the B-T and T-B MAP groups were not significantly different from prechallenge levels. Postchallenge anti-PA and anti-LND peptide GMTs were 22,882 and 16,809 for the T-B MAP group and 7,022 and 9,620 for the B-T MAP group (Fig. 4) . For both MAP-immunized groups there were increases in the mean levels of neutralization postchallenge compared with prechallenge, with postchallenge GMTs of 2,032 and 5,097 for B-T and T-B MAP groups, respectively, compared with prechallenge titers of 549 and 1,651 in these groups (Fig. 4E, 4F) , although the differences were not significant (p = 0.0973 for B-T group; p = 0.7308 for T-B group). The increases in neutralization postchallenge were partially attributable to the effects of a single rabbit in each cohort on the postchallenge TNA analysis. In the B-T MAP group, contributions from the dramatically increased neutralization of the one rabbit with apparent anamnestic immunity increased the GMT. In the T-B MAP group, the absence of serum for analysis from the single nonsurviving rabbit that had undetectable neutralization prechallenge led to an increase in the postchallenge GMT. When the data from these two rabbits were excluded from the analysis, the respective pre-and postchallenge GMTs were 989 and 1,499 for the B-T MAP group and 3,576 and 5,097 for the T-B MAP group.
Serum Ab titers from PA-immunized survivor rabbits were not significantly different from prechallenge Ab titers, whereas postchallenge TNA titers among PA-immunized rabbits (GMT = 836) declined significantly compared with prechallenge neutralization titers (GMT = 1954, p = 0.0379; Fig. 4 ).
All PA-and surviving T-B MAP-immunized rabbits and five of seven B-T MAP-immunized rabbits had extremely low or undetectable levels of LF-specific IgG or IgM in their postchallenge serum, suggesting little or no B. anthracis vegetative cell outgrowth in these rabbits, whereas two rabbits in the B-T MAP group developed detectable de novo LF Ab responses, with LF-specific titers of 2000 and 1700 (Table I) . One of these rabbits, discussed previously, was the sole rabbit that appeared to develop a potent anamnestic response. Unlike all other surviving rabbits, this animal demonstrated clinical symptoms consistent with B. anthracis infection, including lethargy, soft stool, and poor appetite.
LND-specific Ab is not detectable in NHP and human reference PA antisera
We previously showed that significant Ab to the LND region was not elicited in rabbits immunized with PA, a result that was also confirmed in the current studies (37) . Because Ab with specificity for the LND can mediate protection from B. anthracis spore challenge in rabbits, and is therefore a potentially important component of a vaccine response, we evaluated whether LND-specific Ab is present in standardized reference sera from NHPs and human vaccinees immunized with PA-containing formulations. Reference sera obtained through BEI Resources from rhesus and cynomolgus macaques immunized with rPA and from rPA-or AVA-immunized (AVR801) human vaccinees were screened for reactivity with immobilized full-length PA and with the LND peptide sequence by ELISA. Whereas all of the reference sera were shown to have measurable PA immunity, none had detectable Ab to the LND peptide sequence (Fig. 6) . These data suggest that immunization of humans and NHPs with PA-based vaccines does not elicit functional levels of LND-specific Ab. There was no detectable neutralization in the preimmune serum from the rabbits or in the sera of rabbits immunized with an irrelevant T*-containing MAP (data not shown).
Discussion
In this study, we demonstrated that immunization with a totally synthetic peptide vaccine can elicit Ab responses capable of protecting rabbits from a 200-LD 50 challenge with aerosolized spores of B. anthracis Ames strain. To our knowledge, this is the first demonstration of protection against inhalation anthrax mediated by an active immune response to a synthetic peptide vaccine. Evidence presented in this study from screening NHP and human PA reference antisera shows that Ab specific for the LND is unlikely to be a significant component of the immune response to vaccination with AVA, AVP, or PA.
Vaccination with PA, the critical antigenic component of AVA and AVP, or the LND MAPs resulted in anti-PA and TNA titers that protected the rabbits from inhalation challenge. All rabbits with prechallenge TNA titers survived the aerosol challenge. The lone nonsurviving T-B MAP-immunized rabbit had no detectable neutralization prechallenge and, although the anti-PA and anti-LND peptide titers from this rabbit were the lowest within their group, did not indicate an absence of immunity. A similarly TNA-negative rabbit from the B-T MAP group had comparable anti-PA and anti-LND peptide titers and survived challenge. As a result of exposure to PA produced as a consequence of vegetative outgrowth of B. anthracis, this animal developed a potent LND peptide-specific IgG response to challenge consistent with anamnestic immunity, which most likely was responsible for this rabbit's survival. Serum obtained from this rabbit 14 d after challenge demonstrated the highest levels of Ab and TNA titers postchallenge among all PAand MAP-immunized rabbits. Whereas the association between high levels of Ab specific for the LND peptide sequence and high levels of toxin neutralization in vitro, as observed in the serum of this animal, is consistent with previous data on Ab elicited to the LND (36, 37) , the development of anamnestic immunity is somewhat surprising given the use of a heterologous Th cell epitope from P. falciparum in these peptides. We demonstrated in the current study and previously that the LND peptide sequence is devoid of Th cell epitopes in multiple strains of mice (36) . As a consequence, we incorporated the broadly recognized T* helper T cell epitope from P. falciparum into the LND MAPs to effectively stimulate rabbit T cells in support of production of LNDspecific Ab. Rabbit T cells specific for the T* epitope, however, would not be expected to be restimulated upon exposure to Ags produced as a consequence of infection with B. anthracis, yet stimulation of T cells is likely to have played a role in the strong anamnestic immunity observed in this animal. One possible explanation for this finding may be that the 304-319 LND peptide sequence from PA may contain a Th cell epitope for some rabbits. It has recently been noted that PBMCs from the blood of some rPA and AVP vaccinees, as well as individuals surviving cutaneous anthrax, demonstrate responses to the 305-319 peptide sequence in vitro, a result that would not have been predicted from the screening of LND peptides in mice (53) . Indeed, the presence of a Th cell epitope in the 305-319 sequence capable of being recognized by rabbit T cells might also help explain why a MAP displaying only the 305-319 peptide sequence from PA, but no exogenous helper epitope, was shown to be immunogenic in rabbits (37) .
Evidence exists in animal models of anthrax that anamnestic immunity may play an important role in PA-based vaccine protection from anthrax (54, 55) . In the current study, with the exception of two B-T MAP-immune rabbits, no surviving MAP-or PAimmunized rabbits developed de novo LF immunity and, overall, survivor rabbits generally demonstrated declines in their PA titers postchallenge. These data are consistent with minimal spore germination and vegetative cell outgrowth, and are most likely a result of the high levels of neutralizing Ab in the serum of rabbits at challenge (56) . Hermanson et al. (57) , in their studies with rabbits injected with plasmid DNA expressing PA83, also found no evidence of de novo LF-specific Ab production nor identified any biomarkers suggesting vegetative cell outgrowth of B. anthracis in the postchallenge sera of rabbits that had high levels of neutralizing anti-PA Ab in their serum prior to aerosol challenge. Conversely, rabbits immunized with AVA in the same study were found to have lower levels of neutralizing Ab at the time of aerosol challenge, and although all rabbits survived spore challenge, examination of survivor sera from these rabbits revealed significant levels of de novo LF-specific Ab and increases in PA Ab titers. Overall, these data suggest that high levels of neutralizing Ab at the time of aerosol challenge are associated with lower levels of spore germination and vegetative cell outgrowth, and consequently, little or no B. anthracis-associated antigenic stimulation. By contrast, rabbits immunized with AVA or rPA in aluminum-based adjuvants may be less likely to develop such sterile immunity, especially in less ideal immunization and challenge protocols that better model potential real-world scenarios of spore exposure (16) . In such scenarios, some level of spore germination and vegetative cell outgrowth is more likely to occur, and anamnestic immunity may assume a more critical and demonstrable role.
Whereas overall Ab levels in all immune groups declined postchallenge, consistent with a lack of antigenic stimulation, the levels of TNA among the majority of MAP-immune rabbits increased postchallenge compared with prechallenge, although the increases were not statistically significant. This was not the case with PAimmune survivor rabbits, however, in which serum neutralization titers postchallenge demonstrated significant reductions compared with prechallenge levels. The explanation for possible increased neutralization in the serum of LND MAP-immune animals postchallenge is unclear, but one possibility is that PA derived from germination of B. anthracis or PA on the spore surface (58, 59) , although incapable of stimulating anamnestic immunity manifested as increases in overall anti-PA Ab titer by ELISA, is capable of stimulating high-affinity LND-specific B cells that may disproportionately contribute to toxin neutralization. We have previously demonstrated that high-affinity LND-specific Abs are elicited through immunization with LND MAPs and that neutralization of LeTx in vitro is correlated with Ab affinity (36) .
Development of a synthetic peptide vaccine against anthrax could offer potential advantages with regard to safety, reactigenicity, and ease of vaccine manufacture, administration, and storage, compared with other PA-based vaccine formulations. Moreover, because Ab to the LND is capable of mediating protection from lethal spore challenges with B.
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Titers are expressed as the reciprocal of the EC 50 . Lower limit of quantification is 16. could also be strategic in countering malicious attempts to engineer PA to escape neutralizing specificities elicited by AVA and AVP, and other PA-based vaccines and therapeutics (35, 60, 61) . The linear sequences comprising the LND, which are found within the 2b2-2b3 loop of PA, are critical to the translocation of LF and EF into the cytosol, and mutations or deletions in this region, especially those involving the F313-F314, have been shown to completely abrogate the cytotoxicity of LeTx in vitro (38) (39) (40) (41) 62) . The criticality of these loop sequences for LeTx cytotoxicity might hinder any malicious re-engineering of PA to subvert an LND vaccine.
In conclusion, we have demonstrated that immunization with a MAP consisting of the LND peptide sequence aa 304-319 from PA colinearly synthesized with a heterologous Th cell epitope can protect rabbits from a 200-LD 50 aerosol spore challenge with B. anthracis Ames strain. Analysis of NHP and human reference PA antisera suggests that Ab to the LND is not present at meaningful levels in human AVA or AVP vaccinee serum. An efficacious synthetic peptide vaccine targeting the LND has the potential to become a critical component of PA-based vaccination for anthrax.
